Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 789 results for "Ibrutinib"

AbbVie's Imbruvica Has Favorable Response Rate Among Marginal Zone Lymphoma Patients
Nasdaq

Pivotal Trial Finds That Imbruvica Shows Benefit in CLL and SLL

Imbruvica (ibrutinib) improved survival for patients withsmall lymphocytic lymphoma (SLL) andchronic lymphocytic leukemia (CLL), according to study results that were recently presented. Imbruvica (ibrutinib) reduced the risk of progression or death ... CURE Magazine, 9 hours ago
[x]  

22 images for Ibrutinib

Cancer Therapy Advisor, 5 days ago
PharmaVOICE, 1 week ago
Med India, 1 month ago
Cancer Therapy Advisor, 1 month ago
Cancer Therapy Advisor, 1 month ago
Targeted Oncology, 1 month ago
Targeted Oncology, 1 month ago
Nasdaq, 1 month ago
Targeted Oncology, 1 month ago
LLS Community, 1 month ago
MedIndia

VIDEO: Ibrutinib could be game changer for GVHD treatment

SAN DIEGO — Ibrutinib safely and effectively treated patients with chronic graft-versus-host disease who failed at least one line of systemic therapy, according to a late-breaking abstract presented at the ASH Annual Meeting and Exposition.Early ...
 Healio2 weeks ago Ibrutinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease After Transplant  ASH Clinical News2 weeks ago Orphan designation: ibrutinib, for the: treatment of graft-versus-host disease  European Medicines Agency1 month ago Ibrutinib Combination Therapy Safely Treats DLBCL  OncoTherapy Network1 month ago
[x]  

Ibrutinib Results in High Response Rates for Patients With Waldenström Macroglobulinemia

According to a study published in Lancet Oncology , 90 percent of patients (n=28/31) with Waldenström macroglobulinemia (WM) responded to treatment with ibrutinib 420 mg, including 22 (71%) major responses. Meletios A. Dimopoulos, MD, from the ...
 ASH Clinical News4 days ago Ibrutinib 'Remarkable' in Waldenstrom's Macroglobulinemia  Dermatology Online Journal2 weeks ago

Ibrutinib yields durable responses in chronic GVHD

SAN DIEGO — Ibrutinib conferred clinically meaningful and durable responses in a cohort of patients with chronic graft-versus-host disease who had failed after corticosteroids, according to findings presented during the late-breaking abstract ...
 Healio4 weeks ago 'Meaningful' Responses With Ibrutinib in Chronic GVHD  Diabetes Care1 month ago Responses Are High/Durable for Ibrutinib in Chronic Graft Versus Host Disease: Presented at ASH  FirstWord Pharma1 month ago

BRIEF-AbbVie reports positive Phase 2 data for ibrutinib in cGVHD patients

n"Dec 6 Abbvie Inc : * Late-Breaking ibrutinib (imbruvica) data show complete or partial response in two-thirds of patients with chronic graft-versus-host-disease, a frequent and potentially life-threatening complication of stem cell transplant * ...
 Reuters UK1 month ago BRIEF-AbbVie repоrts pоsitive Phase 2 data fоr ibrutinib in cGVHD patients  NewspaperPost1 month ago
Targeted Oncology

Clinical Trial Assesses Non-Hodgkin Lymphoma Drug

By Sarah Plumridge A recent clinical trial published in Lancet Oncology assessed the safety and efficacy of the drug ibrutinib in patients with Waldenstrom's macroglobulinemia, a type of non-Hodgkin lymphoma. Co-author , associate professor of ...
 Health Canal4 days ago TG Therapeutics begins Phase II trial of TGR-1202 and ibrutinib combination to treat DLBCL  Drug Development Technology1 week ago TG Therapeutics, Inc. Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory Diffus  Minyanville1 week ago TGR-1202 Combined With Ibrutinib Demonstrates High Response Rate in CLL/MCL  Targeted Oncology1 month ago
[x]  
Ariva.de

Juno Shows Off Positive Early Data in Leukemia Patients

Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL -- 88% complete marrow response by flow cytometry in efficacy-evaluable patients --100% progression-free ...
 BioSpace1 month ago BRIEF-Juno Therapeutics highlights progress with best-in-class strategy in B-cell Malignancies at ASH  Reuters UK1 month ago Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL  Business Wire1 month ago Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL  American Journal of Managed Care1 month ago
[x]  

Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

89% of study patients, including those with high-risk CLL/SLL, responded to therapy Durable and improving responses also seen in longer follow-up from Phase 3 RESONATE-2 trial This release corresponds to abstracts #233, #234, #2042, #4383 PR ...
 BioSpace1 month ago Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)  Yahoo! Finance1 month ago
[x]  
European Pharmaceutical Review

Price drop means leukaemia CDF drug will be routinely available

The has said that ibrutinib (Imbruvica, Janssen) should be routinely available to some people with chronic lymphocytic leukaemia (CLL). Ibrutinib had only previously been available through the Cancer Drugs Fund (CDF). Following a reduction in its ...
 European Pharmaceutical Review1 month ago Green light for leukaemia drug after price cut  BootsWebMD1 month ago NICE backs Johnson & Johnson's leukaemia therapy Imbruvica after price cut  FirstWord Pharma1 month ago

CAR-T Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR)-T cells of defined composition can be administered with an acceptable early toxicity. Published Online : January 16, 2017 Surabhi ...
 American Journal of Managed Care1 day ago CAR T-Cells of Defined Composition Effective in Ibrutinib-Refractory CLL  American Journal of Managed Care1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less